Srinivas Rao, Ph.D.: President and CEO, Board Director
Dr. Rao is an industry leader with a distinguished track record of material science technology development and commercialization. He serves as advisor and EIR at Phoenix Venture Partners. Until recently, he was Vice President of Corporate Technology at Flextronics International, Ltd. (NASDAQ: FLEX), a multi-billion dollar, global provider of vertically integrated advanced design and electronics manufacturing services. Earlier in his career, he was Vice President of Technology at Solectron Corporation, where he was responsible for engineering and product development, helping grow the company from $190 million to $22 billion in revenues and from one site to over 70 sites worldwide.
Dr. Rao is distinguished alumnus of the Indian Institute of Technology Madras where he earned a B.Tech degree in Metallurgical Engineering, and an MS and PhD in Metallurgy and Materials Science from the Stevens Institute of Technology. He has also held distinguished positions in several technical organizations, editorial boards and, in 2005, served on the Blue Ribbon Task Force on Nanotechnology for the State of California.
Bernard Lemaître: Founder, Board Director
After earning his degree in Engineering, Mr. Lemaître began his career in sales and marketing in positions of increasing responsibility over a 15-year period with Sanofi-Aventis. He then co-founded Stedim SA, a pioneering company developing sterile single- use systems for the pharmaceutical and biotechnology industry. Stedim SA was merged with Sartorius AG. Mr. Lemaître serves as Board Director of Sartorius-Stedim Biotech.
John T. Chen Ph.D. : Board Director
Dr. Chen is a General Partner and co-founder of Phoenix Venture Partners (PVP). He brings over 20 years of experience in venture capital, start-ups, industry, and R&D. Prior to co-founding PVP, Dr. Chen was a Kauffman Fellow at Battery Ventures, where he formulated Battery’s Advanced Materials investment strategy, sourcing over 1,200 investment opportunities and managing several investments with applications in IT and CleanTech, e.g., Lion Cells, Stonybrook Purification and Nanoconduction (acquired). Dr. Chen started his venture capital career at DFJ New England and Navigator Technology Ventures in Boston. Prior to becoming a venture capitalist, Dr. Chen held leadership roles in business, technology, and product development at several startups and leading corporations in the Advanced Materials sector, including Luminus Devices, EM Logix, Surface Logix, and Raychem (acquired). He also led Advanced Materials technology scouting and business development in the areas of energy storage, fuel cells, photonics, and, more broadly, nanotechnology, at Tyco Electronics in the Advanced Technology and Business Development Group following Tyco’s acquisition of Raychem. Dr. Chen earned his BS, MBA, and PhD from MIT. In addition to his investment and board roles with PVP, Dr. Chen serves on the Commercialization Advisory Board for Oregon Built Environment & Sustainability Technologies (BEST) and is an active mentor to several startups through the MIT Venture Mentoring Service.
Nobi Kambe, Ph.D. : Board Director
Dr. Kambe is a Partner and co-founder of Phoenix Venture Partners (PVP). He is a distinguished inventor and serial entrepreneur with deep expertise in nanomaterials. Dr. Kambe has over 50 issued patents and is the founder of three successful start-ups, Nanogram Devices (acquired), Neophotonics (IPO), and Nanogram Corporation (acquired). Earlier in his career, Dr. Kambe was a Research Manager in semiconductor and carbon nanomaterials and devices at Nippon Telegraph & Telephone (NTT) where he became Senior Manager of New Business Strategy in Strategic Planning, with oversight responsibilities for thousands of patetns and hundreds of commercialization and R&D partnerships. Dr. Kambe was also a Managing Director at the International Center for Materials Research (ICMR) in Japan and was the founder of ICMR-USA. Dr. Kambe earned his BS and MS from Keio University and his PhD from MIT. He is a frequent lecturer at the University of Tokyo, Kagawa University, and Keio University, and has been a member of the Evaluation Committee for Nanotechnology at AIST, a major national laboratory in Japan.
Misti Ushio, PhD: Board Director
Misti is a Managing Director at Harris & Harris Group. Prior to joining Harris & Harris Group in 2007, Misti worked at Merck & Co. for over 10 years in BioProcess Research & Development focused on vaccines and biologics, and was a Technology Licensing Officer at Columbia University.
Misti currently serves on the board of Ancora Pharmaceuticals Inc. and OpGen, Inc. She is involved with Ensemble Therapeutics Corporation, Mersana Therapeutics, Inc. and Champions Oncology, Inc. and was previously involved with BioVex, Inc. (acquired by Amgen).
She was graduated from Johns Hopkins University (B.S., Chemical Engineering), Lehigh University (M.S., Chemical Engineering) and University College London (Ph.D., Biochemical Engineering).